Search
CAMELOT study
Design:
- 1991 patients with angiographically significant coronary artery disease (> 20% stenosis)
- diastolic blood pressure < 100 mm Hg
- mean BP = 129/78
Exclusion criteria:
- left main coronary artery stenosis > 50%
- LV ejection fraction < 40%
- moderate-severe heart failure
- use of antihypertensive other than amlodipine or enalapril
Treatment:
- amlodipine 10 mg QD
- enalpril 20 mg QD
- placebo
Duration: 24 months
Results:
- patients receiving amlodipine less likely to experience adverse cardiac events* than placebo group (RR 0.69)
- non-significant risk reduction for amlopidine vs enalapril (RR 0.81) & enalapril vs placebo (RR 0.85)
- both amlodipine & enalapril diminished mean BP by 5/3 mm Hg
* revascularization
hospitalization for
- angina pectoris
- myocardial infarction
- stroke
Study sponsored by manufacturer of amlodipine
Related
antihypertensive agent
coronary artery disease; coronary atherosclerosis (CAD)
General
clinical trial
References
- Journal Watch 25(1):2, 2005
Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D,
Berman L, Shi H, Buebendorf E, Topol EJ; CAMELOT Investigators.
Effect of antihypertensive agents on cardiovascular events in
patients with coronary disease and normal blood pressure:
the CAMELOT study: a randomized controlled trial.
JAMA. 2004 Nov 10;292(18):2217-25.
PMID: 15536108
- Prescriber's Letter 12(1): 2005
Detail-Document#: 210104
(subscription needed) http://www.prescribersletter.com